The pharmaceutical industry is currently witnessing a high-stakes technology arms race that is fundamentally altering how drugs are developed, marketed, and managed. At the heart of this transformation is a battle between two titans—Salesforce and Veeva Systems—each vying to dominate the "agentic" era of life sciences.
As the industry pivots toward autonomous artificial intelligence to navigate the complexities of clinical trials and commercial engagement, Salesforce has signaled a major milestone: over 140 life sciences organizations, including industry powerhouses like Novartis, AstraZeneca, Moderna, and Merck Animal Health, have officially adopted its Agentforce Life Sciences platform.
The Strategic Pivot to Agentic Labor
The term "agentic" has moved from the fringes of Silicon Valley to the center of boardroom discussions in the life sciences sector. Unlike traditional predictive AI, which merely analyzes data, agentic AI refers to systems capable of autonomous action—executing tasks, managing workflows, and making decisions based on complex, regulated datasets.
Salesforce’s recent announcement came at a moment of intense industry scrutiny during the Veeva Commercial Summit in Boston. Joe Ferraro, SVP and GM of Life Sciences at Salesforce, emphasized that the 140-client milestone reflects broad adoption across the entire life sciences spectrum, from clinical engagement and medical affairs to commercial operations and patient support.
"The 140 represents customers across our entire portfolio," Ferraro stated. "Regardless of whether they are using it for patient engagement, clinical engagement, commercial engagement, or medical engagement, they are finding value in the autonomy our platform provides."
A Chronology of the AI Arms Race
To understand the current tension between Salesforce and Veeva, one must look at the historical trajectory of their respective AI strategies.
2014–2016: The Foundation
Salesforce’s AI journey began in earnest a decade ago. In 2014, CEO Marc Benioff declared the company an "AI-first" organization, a strategic shift punctuated by the $390 million acquisition of the machine-learning startup RelateIQ. By 2016, the company launched Einstein, its first CRM-integrated AI, establishing a foothold in predictive analytics that would define its product roadmap for years.
2024: The Rise of Agentforce
The landscape shifted dramatically in September 2024 at Dreamforce, when Salesforce unveiled Agentforce. Branded as "digital labor," the platform was designed to move beyond passive assistance, empowering businesses to deploy agents that function autonomously. Benioff’s goal is ambitious: to empower one billion agents by the end of 2025.
2025–2026: The Competitive Influx
Veeva, the long-standing leader in cloud software specifically for the life sciences industry, has not remained static. Recognizing the threat, Veeva launched its Vault CRM agentic capabilities in late 2025, followed by the announcement of Falcon in May 2026—an agentic platform specifically for drug development.
Throughout 2026, the rivalry intensified. Veeva acquired the AI brand-engagement firm Ostro for $100 million in March 2026 to bolster its conversational AI capabilities, while Salesforce reported a staggering 28.6 trillion AI tokens processed in the first quarter of fiscal 2027—a 152% increase quarter-over-quarter.
The "Headless" vs. "Depth-Inside" Philosophy
One of the most significant technical differentiators between the two companies lies in their approach to integration and accessibility.
Salesforce: The "Headless" Strategy
Salesforce is aggressively pushing a "headless" AI strategy. By leveraging the Model Context Protocol (MCP)—a standard for connecting AI models to data systems—Salesforce is essentially "popping the top" off its platform. This allows clients to surface Salesforce’s compliant workflows inside external AI tools like Anthropic’s Claude.
"I was with a customer yesterday who has made a significant investment in Anthropic, and they are going to use our MCP service to bring all of those compliant workflows directly inside Claude," Ferraro explained. This move is designed to meet customers where they already work, rather than forcing them into a proprietary UI.
Veeva: The "Depth-Inside" Posture
Veeva maintains a different philosophy. Its Vault AI Agents are built to run deep within the Veeva ecosystem. The company argues that by keeping agents inside its own applications, it ensures tighter control over the data, document lifecycle, and regulatory compliance. Rather than "surfacing" agents elsewhere, Veeva focuses on deepening the intelligence within the existing user interface.
Supporting Data and Financial Implications
The financial stakes of this competition are immense. During Salesforce’s Q1 fiscal 2027 earnings call, Benioff labeled agentic AI as the company’s "biggest growth opportunity" since the advent of cloud CRM. With Agentforce annual recurring revenue (ARR) already sitting at $1.2 billion, the market is clearly responding to the promise of automated labor.
For Veeva, the move into agentic labor is an attempt to defend its stronghold. By fixing the model layer for its standard agents—relying on Anthropic and Amazon Bedrock—Veeva provides a "walled garden" that appeals to risk-averse pharmaceutical executives who prioritize security and predictability over the flexibility of an open, headless architecture.
The Compliance Imperative: Navigating the Regulatory Minefield
In the life sciences industry, the primary hurdle for AI is not just capability, but compliance. Large Language Models (LLMs) are inherently probabilistic, which poses a significant risk for highly regulated processes like clinical trials or medical marketing.
Both companies are addressing this through a "deterministic layer."
- Salesforce uses Agent Script, a feature that forces agents to adhere to approved templates, consent statuses, and regulatory guidelines, effectively preventing the AI from "going off-script."
- Veeva relies on its deep contextual integration, ensuring that agents only interact with verified data within the Vault environment.
As Ferraro noted, "The model cannot go off script, because those tools are unavailable. The tools are outside its toolbox."
Implications for the Future of Life Sciences
The shift toward agentic AI is already showing tangible results in operational efficiency. Salesforce has reported that onboarding times for new life sciences clients have dropped to as little as one month, largely due to the ability of forward-deployed engineers to use agents to automate complex configuration tasks that previously required large consultant teams.
However, the implications for the industry are broader than mere speed. The transition signifies a move toward:
- Personalized Engagement: AI agents can now synthesize vast amounts of clinical data to provide personalized, compliant responses to healthcare providers (HCPs) in real-time.
- Autonomous Operations: From clinical trial site monitoring to regulatory document drafting, the "digital labor" force is poised to take over repetitive tasks, freeing human scientists and commercial teams to focus on strategy.
- Vendor Lock-in vs. Ecosystem Flexibility: The divergence between Salesforce’s open, MCP-based approach and Veeva’s integrated Vault ecosystem presents a critical decision for pharma CIOs. Do they prioritize the interoperability of an open, headless AI, or the security and consistency of an application-specific environment?
Conclusion
The battle between Salesforce and Veeva is more than just a fight for market share; it is a fundamental debate about the architecture of the future of healthcare. While Salesforce bets on an open, "headless" future where AI agents can operate across any interface, Veeva is betting that the unique regulatory needs of the life sciences sector demand a tighter, more contained approach.
For the pharmaceutical industry, the winner of this race will likely not be decided by who has the most sophisticated model, but by who can best bridge the gap between the chaotic, probabilistic nature of AI and the rigid, deterministic requirements of global drug regulation. As both companies continue to deploy "digital labor" into the workforce, the nature of work in life sciences is irrevocably changing.
About the Author
